Third, both studies were conducted prior to the regulatory approval of sodium-glucose cotransporter-2 inhibitors and sacubitril/valsartan, and more research is needed to compare the effects of CRT-D vs. CRT-P in NICM patients in the context of novel anti-cardiac failure drug therapy. The gene discussed is SLC5A2; the disease is heart failure.